Navigation Links
Prostate Cancer Study: Most Patients Report Satisfaction After Robotic Surgery
Date:12/3/2012

NEW YORK, Dec. 3, 2012 /PRNewswire/ -- The majority of patients undergoing RALP (robot-assisted laparoscopic prostatectomy) surgery for localized prostate cancer do not regret their treatment decision, according to findings published in The Journal of Urology, December 2012, http://www.jurology.com/article/S0022-5347(12)04453-9/abstract. Analysis indicates the primary factors contributing to postoperative quality of life, and therefore satisfaction or dissatisfaction with treatment choice, are pre- and postoperative sexual potency and urinary control.

(Photo: http://photos.prnewswire.com/prnh/20121203/NY22781 )

The study included 953 consecutive prostate cancer treatment patients with RALP performed by Dr. David Samadi, Vice Chairman, Department of Urology and Chief of Robotics and Minimally Invasive Surgery at New York's Mount Sinai Medical Center. At a median of 11.1 months after robotic surgery, 74 percent completed questionnaires regarding quality of life and treatment decisional regret. Of these patients, 88 percent reported satisfaction with their decision to have RALP. Dr. Samadi performs custom RALP surgery using the Samadi Modified Assisted Robotic Technique (SMART).

In this study Dr. Samadi and his colleagues sought to define specific factors impacting patient decisional regret following RALP for localized prostate cancer. Their analysis focused on the relationship between independent baseline status and quality of life after surgery, namely patient age and erectile and urinary functions before and after surgery.

"It is encouraging that nearly a year after surgery, the majority of my patients are satisfied with their treatment choice and quality of life," said Dr. Samadi. "I believe these findings highlight the importance of pre-op counseling; working one-on-one with patients and their partners to provide a realistic assessment of before and after functions."

Patient-reported data indicated that those with preexisting erectile dysfunction (ED) have greater difficulty with sexual potency after surgery. In terms of regret, however, men with superior preoperative erectile function were more bothered by postoperative sexual issues that those already experiencing some degree of ED. Additionally, patients with severe baseline lower urinary tract symptoms (LUTS) were more regretful after surgery, despite their preexisting urinary problems.

"What we found," explained Dr. Samadi, "is that patient satisfaction with robotic prostate surgery depends on a range of pre- and postoperative variables. This reinforces the need for patient-specific treatment counseling before surgery and a continuing doctor-patient relationship during post-surgery rehabilitation."

Though not included in this study, ongoing patient data indicates that 96 percent of Dr. Samadi's patients regain urinary continence within two to three months of surgery and sexual potency within 12-24 months. To date, Dr. Samadi has performed more than 4,000 successful SMART prostatectomy surgeries.

Related Links:

The Journal of Urology, December 2012 – Click Here  
http://www.jurology.com/article/S0022-5347(12)04453-9/abstract 
http://www.roboticoncology.com 
http://www.smart-surgery.com


'/>"/>
SOURCE roboticoncology.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
2. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
3. Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis
4. US HIFU to Showcase High Intensity Focused Ultrasound for the Treatment of Prostate Cancer at AUA
5. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
6. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
7. Arkansas Prostate Cancer Center Earns High Honor of ACR-ASTRO Accreditation
8. Breakthrough Prostate Cancer Diagnostics
9. New Research Reveals Some Natural Supplements Effective Against Prostate Cancer
10. Prostate Cancer and Bone Health
11. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):